Afya (AFYA) Company Report

Analyst Coverage

Research analysts who have asked questions during Afya earnings calls.

Marcelo Santos

JPMorgan Chase & Co.

5 questions for AFYA

Also covers: AMX, LAUR, MELI +9 more

Flavio Yoshida

Bank of America Merrill Lynch

4 questions for AFYA

Also covers: BDORY, VSTA

Lucca Marquezini

Itaú BBA

4 questions for AFYA

Also covers: VSTA

Andre Salles

UBS

3 questions for AFYA

Mauricio Cepeda

BTG Pactual

3 questions for AFYA

Also covers: AUNA, LAUR

Lucas Nagano

Morgan Stanley

2 questions for AFYA

Also covers: LAUR, VSTA

Flavio

Bank of America

1 question for AFYA

Gustavo Miele

Goldman Sachs

1 question for AFYA

Also covers: HYPMY

Hernan

Citibank

1 question for AFYA

Also covers: PAGS

Jessica Mehler

Bank of America

1 question for AFYA

Also covers: VSTA

Leandro Bastos

Citibank

1 question for AFYA

Also covers: AUNA, HYPMY

Mauricio Sepeira

Morgan Stanley

1 question for AFYA

Mirela Rodrigues de Oliveira

Bank of America

1 question for AFYA

Also covers: VSTA

Samuel Alves

BTG Pactual

1 question for AFYA

Also covers: AUNA

Latest news

Recent press releases and 8-K filings for AFYA.

Afya Announces Fourth Quarter and Full-Year 2025 Financial Results

AFYA

Earnings

Guidance Update

Dividends

Afya Limited reported strong full-year 2025 financial results, with Revenue increasing 11.9% year-over-year to R$3,697.3 million and Adjusted EBITDA growing 15.4% to R$1,680.3 million. Net Income rose 18.4% to R$768.4 million, and Basic EPS increased 18.7% to R$8.32 for the twelve-month period ended December 31, 2025.
The company achieved its full-year 2025 guidance for both Revenue and Adjusted EBITDA.
Afya also provided 2026 guidance, projecting Revenue between R$3,950 million and R$4,100 million and Adjusted EBITDA between R$1,700 million and R$1,800 million.
The Board of Directors approved a dividend distribution of R$307.4 million, representing R$3.446838 per share, payable on April 6, 2026, to shareholders on record as of March 25, 2025.
Afya significantly reduced its Net Debt (excluding IFRS 16) by 24.5% year-over-year to R$1,369.5 million, resulting in a Net Debt/Adjusted EBITDA ratio of 0.8x as of December 31, 2025.

2 days ago

Press Release

Afya Limited Announces Dividend Distribution

AFYA

Dividends

Share Buyback

Afya Limited's Board of Directors approved a dividend distribution of R$307.4 million, which represents 40% of the Company's consolidated net income for the year ended December 31, 2025.
The dividend per share is R$3.446838, payable in U.S. dollars on April 6, 2026, to shareholders on record as of March 25, 2025.
The company also has approximately 60% of its current authorized share repurchase program remaining until December 2026, and expects total distributions (dividends and buyback) to be 50% of its consolidated net income for 2025.

2 days ago

Press Release

Afya Reports Strong Q4 and Full-Year 2025 Results, Issues 2026 Guidance, and Announces Dividend

AFYA

Earnings

Guidance Update

Dividends

Afya reported strong full-year 2025 financial results, with revenue reaching BRL 3,697 million, a 12% increase year-over-year, and adjusted EBITDA growing 15% to BRL 1,680 million. Net income increased 18% to BRL 768.4 million, and basic EPS grew 19% to BRL 8.32.
The company issued 2026 guidance, projecting revenue between BRL 3.95 billion and BRL 4.1 billion and adjusted EBITDA between BRL 1.7 billion and BRL 1.8 billion. The implied 2026 EBITDA margin is expected to be slightly lower than 2025 due to increased investments in continuing education and medical practice solutions, and a segment mix effect.
Afya announced a cash dividend of BRL 307.4 million, equivalent to BRL 3.45 per share, representing 40% of its 2025 net income, payable on April 6, 2026. The company also continues its share repurchase program, with 60% of the authorized buyback program remaining until December 2026, and expects to distribute 50% of 2025 consolidated net income through dividends and buybacks.
Strategic investments are planned for continuing education and medical practice solutions to enhance platform integration, expand audience reach, and deepen engagement across the physician lifecycle, aiming for long-term monetization and maintaining low customer acquisition costs for undergrad students.

2 days ago

Transcript

Afya Reports Strong Q4 and Full-Year 2025 Results, Issues 2026 Guidance and Announces Dividend

AFYA

Earnings

Guidance Update

Dividends

Afya reported full-year 2025 revenue of BRL 3,697 million, a 12% year-over-year increase, and adjusted EBITDA of BRL 1,680 million, up 15% year-over-year, with an adjusted EBITDA margin of 45.4%. Net income for the year reached BRL 768.4 million, an 18% growth, and basic EPS was BRL 8.32, a 19% increase.
For Q4 2025, revenue was BRL 913 million, an 8% increase, and adjusted EBITDA was BRL 389 million, up 6%. The company ended the year with BRL 1,548 million in cash flow from operating activities and a net debt of BRL 1,369 million, resulting in a leverage of 0.8x (net debt excluding IFRS 16 divided by adjusted EBITDA).
Afya provided 2026 guidance, expecting revenue between BRL 3.95 billion and BRL 4.1 billion and adjusted EBITDA between BRL 1.7 billion and BRL 1.8 billion. The implied EBITDA margin for 2026 is anticipated to be lower than 2025 due to planned investments in continuing education and medical practice solutions segments.
The company announced a cash dividend of BRL 307.4 million (BRL 3.45 per share), representing 40% of its 2025 net income, payable on April 6, 2026. Afya also continues its share repurchase program, with approximately 60% of the authorized buyback remaining until December 2026, aiming to distribute 50% of 2025 consolidated net income through dividends and buybacks.

2 days ago

Transcript

Afya Reports Strong FY 2025 Results and Issues 2026 Guidance

AFYA

Earnings

Guidance Update

Dividends

Afya reported robust fiscal year 2025 results, with revenue growing 12% year-over-year to BRL 3,697 million and adjusted EBITDA increasing 15% year-over-year to BRL 1,680 million, achieving a 45.4% adjusted EBITDA margin.
The company issued its 2026 guidance, expecting revenue between BRL 3.95 billion and BRL 4.1 billion and adjusted EBITDA between BRL 1.7 billion and BRL 1.8 billion.
Afya announced a cash dividend of BRL 307.4 million, or BRL 3.45 per share, representing 40% of its 2025 net income, payable on April 6, 2026.
The company's leverage improved significantly, with net debt to adjusted EBITDA decreasing from 1.2x to 0.8x by the end of 2025.
The implied lower EBITDA margin for 2026 (approximately 43.5% at the midpoint) is due to strategic investments in continuing education and medical practice solutions, and a shift in the segment growth mix.

2 days ago

Transcript

Afya Limited Announces Strong Q4 and Full-Year 2025 Financial Results

AFYA

Earnings

Guidance Update

Share Buyback

Afya Limited reported FY25 Revenue of R$3,697.3 million, an 11.9% YoY increase, and Adjusted EBITDA of R$1,680.3 million, up 15.4% YoY. Basic EPS grew 18.7% for the full year ended December 31, 2025.
The company achieved its seventh consecutive year of meeting or exceeding revenue and Adjusted EBITDA guidance in 2025 and provided 2026 guidance with expected Revenue between R$3,950 million and R$4,100 million and Adjusted EBITDA between R$1,700 million and R$1,800 million.
Afya's Board of Directors declared a cash dividend of R$307.4 million, corresponding to 40% of 2025 consolidated net income, and authorized a new share repurchase program for up to 4,000,000 Class A common shares through December 31, 2026.
The company reduced its Net Debt (excluding IFRS 16) to R$1,369.5 million as of December 31, 2025, a decrease of R$445.4 million compared to December 31, 2024, resulting in a Net Debt to Adjusted EBITDA ratio of 0.8x.

2 days ago

6-K

Afya Limited Announces Dividend Distribution

AFYA

Dividends

Share Buyback

Afya Limited's Board of Directors approved a dividend distribution of R$307.4 million, which represents 40% of the company's consolidated net income for the year ended December 31, 2025.
The dividend per share is R$3.446838, payable in U.S. dollars on April 6, 2026, to shareholders on record as of March 25, 2025.
This dividend, combined with the ongoing share repurchase program, is expected to result in a total distribution of 50% of the company's consolidated net income for 2025.

2 days ago

6-K

Afya Limited Reports Full Year 2025 Unaudited Consolidated Financial Results

AFYA

Earnings

Debt Issuance

Share Buyback

Afya Limited reported revenue of R$3,697,255 thousand and net income of R$768,443 thousand for the year ended December 31, 2025.
The company's basic earnings per common share was R$8.32 for the year ended December 31, 2025.
Net cash flows from operating activities reached R$1,531,587 thousand for the year ended December 31, 2025.
Afya Limited issued R$1,500,000 thousand in commercial notes on October 15, 2025, and initiated a share repurchase program with a R$77,002 thousand cash outflow during 2025.
A dividend distribution of R$129,784 thousand was approved on March 12, 2025, based on the consolidated net income for the year ended December 31, 2024.

2 days ago

6-K

Afya Announces Medical Seats Increase in Abaetetuba

AFYA

New Projects/Investments

Revenue Acceleration/Inflection

Afya Limited announced that the Ministry of Education (MEC) has authorized an increase of 63 medical seats for its Afya Abaetetuba campus.
This authorization brings Afya Abaetetuba's total medical seats to 113, contributing to Afya's overall portfolio of 3,766 approved medical seats.
The capacity for these additional seats was enabled by Afya Cametá, an approved but non-operating medical school in the same health region, not becoming operational.

Feb 6, 2026, 1:11 PM

6-K

Afya Announces Third Quarter and Nine Months 2025 Financial Results

AFYA

Earnings

Guidance Update

Debt Issuance

Afya Limited reported strong financial results for Q3 2025, with revenue increasing 10.4% YoY to R$928.5 million and Adjusted EBITDA growing 14.6% YoY to R$398.9 million. For the nine months ended September 30, 2025, revenue increased 13.4% YoY to R$2,784.3 million, and Adjusted EBITDA rose 18.5% YoY to R$1,291.7 million.
The company reaffirmed its full-year 2025 guidance, projecting revenue between R$3,670 million and R$3,770 million and Adjusted EBITDA between R$1,620 million and R$1,720 million.
As of September 30, 2025, Afya's Net Debt (excluding IFRS 16) decreased to R$1,342.2 million, a reduction of R$472.7 million from December 31, 2024, driven by solid cash flow from operating activities which reached R$1,291.5 million for the nine-month period. The Operating Cash Conversion ratio was 101.5%.
Subsequent to the quarter, Afya issued R$1,500 million in commercial notes on October 15, 2025, and repurchased all 150,000 Series A perpetual convertible preferred shares for R$831,600 on November 3, 2025. The company also received authorization to increase medical school seats by 100, reaching 3,753 total approved medical school seats.